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Background/Aims: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor 
prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who 
were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year 
survival rate and its prognostic factors among HCC patients. Methods: In total, 257 patients who were consecutively 
diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We 
analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and 
determined the independent prognostic factors affecting survival.  Results:  The patients were aged 59±10 years 
(mean±SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 
1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node 
metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other 
treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a 
second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone 
(P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM 
stage were found to be independent prognostic factors for survival among HCC patients. Conclusions: This retrospective 
cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center. 
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INTRODUCTION
Hepatocellular carcinoma (HCC), which shows a grave 
morbidity and mortality, is the third most common malignancy 
following stomach and lung cancers in Korea.
1,2 HCC has a 
very poor prognosis in comparison with other solid tumors 
because HCC rapidly progresses with its aggressive biological 
behavior and is usually diagnosed at an advanced stage. 
Furthermore, the majority of HCC develops in the background 
of chronic liver diseases such as liver cirrhosis, which makes 
a curative treatment more difficult.
3 Nevertheless, the 5-year 
survival rate of HCC has slightly improved from 11.0% in 
1993-1997 to 14.7% in 1998-2002 in Korea,
4 and several 
large-scale studies have also reported modest improvements 
in the survival of HCC patients worldwide during the last 
few decades.
5,6 It is expected that the survival rates of HCC 
patients will continue to increase with strict application of 
screening/surveillance programs using alpha-fetoprotein Sang Seok Lee, et al. Survival analysis of hepatocellular carcinoma  49
Figure 1. Treatment algorithm for hepatocellular carcinoma (HCC). 
RFA, radiofrequency ablation; TACE, transcatheter arterial 
chemoembolization.
(AFP) and abdominal ultrasonography and with exquisite 
development of treatment modalities, such as liver transplan-
tation, hepatic resection, radiofrequency ablation (RFA), 
transcatheter arterial chemoembolization (TACE), and 
molecularly targeted therapies. Although many studies reported 
outcomes of HCC patients according to the treatment 
modalities,
7-13 only a few studies have reported survival- 
related analysis in all patients who were consecutively 
diagnosed and treated in a single institution in Korea.
14
The aim of this study was to perform survival analysis and 
to identify possible prognostic factors for survival of HCC 
patients who were diagnosed and treated for a given period 
of time, thereby providing useful information on predicting 
prognostic factors according to clinical characteristics, 
tumor staging, and treatment modalities. 
PATIENTS AND METHODS
Patients
Between January 2000 and December 2003, 308 patients 
who were diagnosed as HCC at Dankook University 
Hospital were retrospectively enrolled. HCC was diagnosed 
according to the guidelines of the Korea Liver Cancer Study 
Group and the National Cancer Center.
14 Fifty-one patients 
with inadequate data, prior initial treatments for HCC at 
other hospitals, or interruption to follow up were excluded, 
leaving 257 patients followed until death or until December 
2008.
Treatment methods
Patients received one of five initial treatment modalities: 
hepatic resection, RFA, TACE, systemic chemotherapy, or 
supportive care. The choice of initial treatment was based on 
the Child-Pugh classification and tumor staging (Fig. 1). 
RFA was performed percutaneously using Cool tip electrodes 
(Valleylab, Burlington, MA, USA) under ultrasound guidance. 
TACE was performed using adriamycin-lipiodol emulsion 
and/or absorbable gelatin sponge particles (Gelfoam, Upjohn 
Co., MI, USA). Computed tomography (CT) or magnetic 
resonance imaging (MRI) and the serum AFP level were 
checked every three to six months after curative treatments 
and every two to three months after TACE. If an evidence of 
tumor recurrence was noted in these tests, TACE was 
performed as a second-line treatment.
Analysis of survival and prognostic factors
We reviewed patients’ records and examined the following 
demographic and clinical parameters: age, sex, initial 
symptoms, tumor etiology, biochemistry with liver tests, and 
hematological and radiological data. All data including 
Child-Pugh classification and modified 5th UICC/TNM 
tumor stage
15 were determined at the time of HCC 
diagnosis. We analyzed the survival of patients according to 
initial treatments: surgical resection, RFA, TACE, systemic 
chemotherapy, or supportive care; we also subanalyzed in 
two parts of the HCC patients who received TACE as a 
second-line treatment: TACE after surgical resection and 
TACE after RFA. The study was performed in compliance 
with the ethics principles of the Declaration of Helsinki with 
Good Clinical Practice guidelines.
Statistics
Statistical analysis was performed with SPSS version 12.0 
software (SPSS Inc., Chicago, IL, USA). Survival curves 
were obtained and verified by the Kaplan-Meier method 
with a log-rank test. To identify baseline predictors of 
survival at the time of HCC diagnosis, univariate and 
multivariate regression analysis were performed using the 
log-rank test and Cox’s proportional hazard regression 
model, respectively. Statistical significance was defined as a 
P-value less than 0.05.50  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
RESULTS
Baseline characteristics
Baseline characteristics are summarized in Table 1. Male 
gender (77%) was predominant, and the mean age was 59 ± 
10 years. Hepatitis B virus (65.4%) was the most common 
underlying cause of HCC, and abdominal pain (39.3%) was 
the most common initial presenting symptom. Two hundred 
seven patients (80.5%) were Child-Pugh class A or B. One 
hundred sixty-five patients (64.2%) had a single nodule, and 
175 patients (68.1%) had accompanying portal vein throm-
bosis. Serum AFP levels were elevated above 400 ng/mL in 
106 patients (41.2%). One hundred forty-five patients 
(56.4%) were classified as TNM stage III or IV. 
Survival according to clinical and tumor 
characteristics
Two hundred twenty-three patients (86.8%) died during 
the follow-up period, and 1-, 3-, and 5-year survival rates 
were 44.4%, 21.0% and 12.1%, respectively. The overall 
median survival of all patients was 10.8 months (Table 1, 
Fig. 2A). The 5-year survival rate of patients without 
symptoms was higher than that of patients with at least one 
symptom (21.1% vs. 13.3% [bleeding], P<0.01; Table 1). 
The 5-year survival rate of patients with Child-Pugh class A 
was higher than that of patients with class B (24.0% vs. 
4.9%, P<0.01; Table 1). None of the patients with Child- 
Pugh class C survived 5 years; their median survival was 7.5 
months (Fig. 2B). The 5-year survival rate of patients with 
an AFP level less than 20 ng/mL was higher than that of 
patients with an AFP level equal to or more than 400 ng/mL 
(21.8% vs. 7.5%, P<0.01; Table 1, Fig. 2C). The 1-, 3-, and 
5-year survival rates were significantly different according 
to tumor characteristics, such as size, type, and portal vein 
thrombosis (Table 1). The TNM staging system showed a 
significant difference in the probability of survival across 
the different stages (P<0.01). Patients with TNM stage I and 
II had a median survival of 24 and 20.4 months, respectively, 
and patients with TNM stage IV had a median survival of 
less than 8 months (Table 1, Fig. 2D).
Survival according to treatment modalities
For initial treatment, 17 patients (6.6%) underwent surgical 
resection, 19 (7.4%) underwent RFA, 135 (52.5%) underwent 
TACE, 2 (0.8%) received systemic chemotherapy, and 84 
(32.7%) received supportive care. The survival of the 
patients was analyzed on the basis of the initial treatment 
adopted in patients with Child-Pugh class A or B (Table 2). 
In patients with TNM stage I and II, the 5-year survival rates 
of patients who underwent surgical resection, RFA, and 
TACE were significantly different (75.0%, 27.3%, and 19.0%; 
P<0.01). In patients with TNM stage III, the 5-year survival 
rate of patients who underwent surgical resection was higher 
than that of patients who received TACE (66.7% vs. 10.0%; 
P<0.01). No significant difference was observed in survival 
rates between the patients with TNM stage IV-a and IV-b.
In analysis of the patients who received supplementary 
TACE as a second-line treatment (Table 3), the 5-year 
survival rate of patients who underwent TACE after surgical 
resection was higher than that of patients who underwent 
only surgical resection (85.7% vs. 50%; P=0.02). No 
significant difference was seen in survival rates between the 
patients who underwent TACE after RFA and those who 
underwent only RFA. 
Prognostic factors
Univariate analysis showed that etiology (P=0.02), initial 
symptom (P<0.01), Child-Pugh class (P<0.01), AFP level 
(P<0.01), tumor size (P<0.01), tumor type (P<0.01), portal 
vein thrombosis (P<0.01), and TNM staging (P<0.01) were 
significant baseline predictors of survival in patients with 
HCC (Table 1). Multivariate analysis identified initial 
symptom, Child-Pugh class, AFP level, tumor size, portal 
vein thrombosis, and TNM stage as independent baseline 
predictors of survival (Table 4).
DISCUSSION
Despite the high prevalence and mortality of HCC in 
Korea, few studies have stratified the survival outcomes 
according to liver functions, tumor stages, and treatment 
modalities in a cohort of HCC patients.
14 Most studies 
released limited reports about survival outcomes in HCC 
patients who underwent a certain therapy.
16,17 In this study, 
clinical data were collected from all patients who were 
treated and followed at a single center for a given period of 
time and analyzed according to the clinical staging system 
and treatment modalities proposed by the Korea Liver 
Cancer Study Group and the National Cancer Center.
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Table 1. Hepatocellular carcinoma (HCC) survival rates according to clinical and tumor characteristics
Clinical characteristics Number of patients 1-YSR 3-YSR 5-YSR Median survival, mon P-value
*
Overall 257 44.4 21.0 12.1 10.8
Age, yr 0.96
<50 41 41.5 26.8 17.1 10.3
≥50 216 44.9 19.9 11.1 10.9
Gender 0.82
Male  198 43.4 21.2 12.1 10.6
Female 59 47.5 20.3 11.9 11.4
Etiology 0.02
HBV 168 41.1 17.3 8.9 10.2
HCV  13 53.8 23.1 23.1 14
HBV+HCV 3 100.0 100.0 33.3 NR
Alcohol 50 54.0 24.0 14.0 14.2
Unknown 23 34.8 30.4 21.7 9.2
Symptom <0.01
No symptom 90 66.7 33.3 21.1 22.6
Abdominal pain 101 32.7 17.8 7.9 8.9
Abdominal distension 36 33.3 5.6 5.6 9
Encephalopathy 4 50.0 25.0 0.0 12
Bleeding 15 33.3 20.0 13.3 9
Others 11 18.2 0.0 0.0 7.3
Child-Pugh class <0.01
A 104 63.5 32.7 24.0 20.8
B 103 36.9 15.5 4.9 9.5
C 50 20.0 8.0 0.0 7.5
AFP, ng/mL <0.01
<20 87 64.4 37.9 21.8 23.5
20-399 64 45.3 14.1 6.3 11.0
≥400 106 27.4 11.3 7.5 8.3 0.15
Number of tumor nodules
1 165 49.1 24.2 15.8 11.8
2-3 62 35.5 14.5 6.5 9.3
≥4 30 36.7 16.7 3.3 9.5
Size of tumor, cm <0.01
<2 58 72.4 37.9 17.2 24
2-5 104 50.0 25.0 16.3 12
5-10 36 33.3 8.3 5.6 9
>10 59 13.6 5.1 3.4 6.9
Type of tumor <0.01
Uninodular 121 61.2 30.6 19.0 17.8
Multinodular 63 46.0 20.6 7.9 11.1
Diffuse 14 21.4 7.1 7.1 7.6
Massive 59 13.6 5.1 3.4 6.9
Portal vein thrombosis <0.01
Absent  82 57.7 27.4 16.6 16.4
Present 175 15.9 7.4 2.4 7.1 <0.01
TNM stage
I 18 77.8 44.4 22.2 24
II 94 64.9 33.0 22.3 20.4
III 80 32.5 13.8 7.5 8.9
IV-a 42 21.4 9.5 0.0 7.6
IV-b 23 17.4 0.0 0.0 7.3
* P-values are calculated using univariate regression analysis with a log rank test.
YSR, year survival rate; yr, year; HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not reached; AFP, alpha fetoprotein; TNM, 
tumor node metastasis.52  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
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Figure 2. Kaplan-Meier survival curves according to clinical and tumor characteristics. (A) The overall median survival of the 257 
patients was 10.8 months. (B) The 5-year survival rates of patients with Child-Pugh class A, B, and C were 24, 4.9, and 0%, respectively 
(P<0.01). (C) The 5-year survival rate was higher in patients with an alpha-fetoprotein (AFP) level of <20 ng/mL than in those with 
an AFP level of ≥20 ng/mL (P<0.01). (D) Analysis of tumor node metastasis (TNM) staging revealed that the probability of survival 
differed significantly with the stage (P<0.01).
Table 2. Survival rates according to treatment modalities and tumor node metastasis (TNM) stage in patients with Child-Pugh class A or B
TNM stage Treatment No 1-YSR 3-YSR 5-YSR Median survival, mon P-value
*
I, II Resection 12 100.0 91.7 75.0 NR <0.01
RFA 11 81.8 36.4 27.3 27.0
TACE 63 73.0 33.3 19.0 22.2
Conservative 12 25.0 8.3 8.3 8.0
III Resection  3 66.7 66.7 66.7 NR <0.01
RFA  1 100.0 0.0 0.0 18.0
TACE 40 50.0 17.5 10.0 12.0
Conservative 22 9.1 9.1 0.0 6.6
IV-a TACE 17 29.4 11.8 0.0 8.5 0.11
Conservative 10 10.0 0.0 0.0 6.7
IV-b TACE  6 50.0 0.0 0.0 12
Chemotherapy  1 0.0 0.0 0.0 -
Conservative  8 0.0 0.0 0.0 -
* P-values are calculated using univariate regression analysis with a log rank test.
TNM, tumor node metastasis; No, number; YSR, year survival rate; NR, not reached; RFA, radiofrequency ablation; TACE, transcatheter 
arterial chemoembolization.Sang Seok Lee, et al. Survival analysis of hepatocellular carcinoma  53
Table 4. Independent predictive factors for survival in HCC patients
Variables Relative risk 95% CI P-value
*
Symptom No symptom 1
Abdominal pain 1.53 1.10-2.12
Abdominal distension 1.52  0.95-2.42 0.01 
Encephalopathy 0.81  0.26-2.49 0.08 
Bleeding 1.56 0.86-2.83 0.71 
Others 3.16  1.61-6.17 0.13 
Child-Pugh class A 1 
B 1.79  1.31-2.43 <0.01
C 2.46 1.68-3.60 <0.01 
AFP, ng/mL <20 1 
20-399 1.77 1.22-2.55 <0.01 
≥400 1.40  0.98-1.99 0.06 
Tumor size, cm <2 1 
2-5 1.24  0.83-1.87 0.28 
5-10 2.46 1.50-4.03 <0.01 
>10 2.69  1.69-4.26 <0.01 
PVT Absent 1 
Present 1.53  1.05-2.25 0.03 
TNM stage I 1 
II 1.28  0.69-2.36 0.43 
III 2.59 1.40-4.78 <0.01 
IV-a 3.54  1.85-6.75 <0.01 
IV-b 6.27 3.07-12.7 <0.01 
* P-values are calculated using multivariate regression analysis with Cox’s proportional hazard model.
HCC, hepatocellular carcinoma; CI, confidence internal; AFP, alpha fetoprotein; PVT, portal vein thrombosis; TNM, tumor node 
metastasis.
Table 3. Survival rates according to second-line treatment modalities in HCC patients
1st treatment 2nd treatment No 1-YSR 3-YSR 5-YSR Median survival, mon P-value
*
Resection TACE  7 100.0 100.0 85.7 NR 0.02
Resection - 10 80.0 70.0 50.0 60
RFA  TACE  8 75.0 37.5 37.5 20.0 0.32
RFA - 11 54.5 18.2  0.0 15.0
* P-values are calculated using univariate regression analysis with a log rank test.
HCC, hepatocellular carcinoma; No, number; YSR, year survival rate; TACE, transcatheter arterial chemoembolization; NR, not 
reached; RFA, radiofrequency ablation.
expect that this study can provide appropriate information 
about the clinical characteristics, prognostic factors, and 
survival outcomes of HCC patients in Korea. 
In the present study, the overall 5-year survival rate of 
HCC patients was not higher than that reported through 
two population-based studies in the years 1998 to 2002,
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hich might be caused by the inability of patients with 
relatively early stages and preserved liver function to 
receive curative treatment. About 12% of patients with 
Child-Pugh class A or B and TNM stage I or II received only 
conservative treatment because of poor economic status and 
inadequate cooperation to treatment.
When planning an optimal treatment for HCC patients, 
considering hepatic reserve function as well as tumor stage 
is very important. Although the TNM staging system for 
HCC does not consider variables indicative of liver function, 
this system is still sufficiently powerful enough to predict a 
patient’s prognosis and to aid in determining treatment 
options with the assistance of laboratory parameters readily 
available in clinical settings. Without exception even in this 
study, this staging system, as expected, revealed a significant 
difference in the probability of survival across the different 
stages in HCC patients.
Besides tumor stage and remaining liver function, 
treatment modality is one of the most important factors 
directly affecting the survival and prognosis of patients.
19 In 
patients with relatively preserved liver function, such as 
those in Child-Pugh class A or B and early TNM stage I or II, 
the median survival period of patients who underwent 
surgical resection could not be estimated due to not reaching 
a survival rate of 50%, while the median survival period of 
patients who received RFA or TACE were 27 or 22.2 
months, respectively, which was longer than that reported 
previously.
20-22 Additionally, in patients with TNM stage 
III, surgical resection statistically showed the best treatment 
results; however, it is inappropriate to grant its clinical 
significance because the number of patients who received 
this operation in this stage was limited, as most patients 
received TACE. 
Park et al
23 reported that the one-, three-, and five-year 
survival rates after TACE were 61%, 29%, and 15%, 
similar to the results of our study. TACE can improve the 
survival of patients with unresectable HCC;
24,25 in the 
present study, the survival rates of patients who underwent 
TACE were higher than those who received conservative 
treatment. Interestingly, the median survival of patients 
treated with TACE was shorter in TNM stage IV-a than in 
those with TNM stage IV-b (8.5 vs. 12 months). This result 
may reflect that the portal vein invasion has a worse 
influence than distant metastasis on survival for HCC 
patients with preserved liver function.
As HCC is frequently observed by recurrence or 
metastasis after curative management, such as surgical 
resection or RFA,
26-29 multimodality treatment has been 
frequently performed. This study analyzed survival rates in 
patients who received TACE as a second-line treatment 
modality after surgical resection or RFA. When compared 
with resection only, second-line TACE after resection 
revealed significantly better results in survival rates and 
median survival periods. Second-line TACE after RFA also 
showed longer survival times even if it was not statistically 
significant when compared with RFA only. TACE is a 
treatment modality most frequently applied to patients with 
HCC, and its survival benefit is known.
30,31 The beneficial 
role of TACE as a second-line therapy in HCC could be 
expected. However, TACE in the present study was applied 
to the patients with an evidence or suspicion of recurrence 
after curative treatments such as resection or RFA in terms 
of optional therapy but not adjuvant one. Further study 
including a large number of patients undergoing multimodality 
treatments should be performed through a prospective 
cohort of HCC.
Several investigations analyzed predictive factors for 
survival of patients with HCC.
14,32,33 In our study, initial 
symptoms, Child-Pugh classification, serum AFP level, 
tumor size, portal vein thrombosis, and TNM staging were 
identified as independent prognostic factors for HCC. 
However, this is a single-center study, and liver transplantation 
was not available in our institution during this study period, 
which is possibly a limiting factor with respect to generalizing 
these results. 
In summary, we identified the clinical characteristics, 
survival rates, and independent prognostic factors affecting 
survival in a retrospective cohort of HCC patients. This 
cohort analysis may provide useful information of prognosis 
predictability in HCC patients, especially for a prospective 
cohort study in the future.
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